BR9907166A - Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina - Google Patents

Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina

Info

Publication number
BR9907166A
BR9907166A BR9907166-5A BR9907166A BR9907166A BR 9907166 A BR9907166 A BR 9907166A BR 9907166 A BR9907166 A BR 9907166A BR 9907166 A BR9907166 A BR 9907166A
Authority
BR
Brazil
Prior art keywords
compound
amidine
pharmaceutical composition
pharmaceutically acceptable
group
Prior art date
Application number
BR9907166-5A
Other languages
English (en)
Inventor
Sherif I Badawy
Donna L Gilbert
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9907166A publication Critical patent/BR9907166A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

''COMPOSIçãO FARMACêUTICA E PROCESSO PARA ESTABILIZAR UM COMPOSTO POSSUINDO UM GRUPO éSTER OPCIONAL E UM GRUPO à BASE DE AMIDINA'' A presente invenção refere-se a uma composição farmacêutica que compreende um tablete ou uma cápsula que contém uma quantidade farmacologicamente eficaz de um composto farmacêutico, ou um seu sal farmaceuticamente aceitável, contendo um grupo à base de amidina e um grupo éster opcional, um veículo sólido farmaceuticamente aceitável, e um ácido farmaceuticamente aceitável em uma proporção para modificar o pH da composição até substancialmente o do composto ao pH de estabilidade máxima. Essa composição é preparada ao se adicionar água durante a fabricação da formulação, e ao se colocar o composto durante a fabricação da formulação em contato com um ácido farmaceuticamente aceitável que tem um pH em uma solução aquosa saturada que é substancialmente aquele do composto ao pH de estabilidade máxima.
BR9907166-5A 1998-01-16 1999-01-14 Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina BR9907166A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7171298P 1998-01-16 1998-01-16
PCT/US1999/000748 WO1999036096A1 (en) 1998-01-16 1999-01-14 Pharmaceutical formulations and processes for their preparation

Publications (1)

Publication Number Publication Date
BR9907166A true BR9907166A (pt) 2000-10-24

Family

ID=22103090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907166-5A BR9907166A (pt) 1998-01-16 1999-01-14 Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina

Country Status (16)

Country Link
US (1) US6136833A (pt)
EP (1) EP1042002A1 (pt)
JP (1) JP2002509120A (pt)
KR (1) KR20010024855A (pt)
CN (1) CN1288385A (pt)
AR (1) AR016017A1 (pt)
AU (1) AU746284C (pt)
BR (1) BR9907166A (pt)
CA (1) CA2314148A1 (pt)
EA (1) EA200000772A1 (pt)
HR (1) HRP990014A2 (pt)
IL (1) IL136635A0 (pt)
NZ (1) NZ505080A (pt)
PL (1) PL342011A1 (pt)
WO (1) WO1999036096A1 (pt)
ZA (1) ZA99168B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US20020160441A1 (en) * 1998-06-02 2002-10-31 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
JP2002326925A (ja) * 2001-04-27 2002-11-15 Asahi Breweries Ltd 造粒物および錠剤の製造方法
JPWO2003094889A1 (ja) * 2002-05-13 2005-10-13 第一製薬株式会社 凍結乾燥物
US7273627B2 (en) * 2004-07-20 2007-09-25 Sukanya Nimmannit Botanical compositions having hypoglycemic, hypolipidemic and antimicrobial activities for maintaining good health in normal person and diabetic patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1287674A (en) * 1969-07-21 1972-09-06 Ici Australia Ltd Injectable compositions
EP0730590B1 (en) * 1993-11-24 2001-01-17 Dupont Pharmaceuticals Company isoxazoline and isoxazole fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists

Also Published As

Publication number Publication date
CA2314148A1 (en) 1999-07-22
EA200000772A1 (ru) 2000-12-25
AU746284C (en) 2003-01-16
AU2115699A (en) 1999-08-02
JP2002509120A (ja) 2002-03-26
NZ505080A (en) 2002-09-27
EP1042002A1 (en) 2000-10-11
AR016017A1 (es) 2001-05-30
PL342011A1 (en) 2001-05-07
WO1999036096A1 (en) 1999-07-22
HRP990014A2 (en) 1999-10-31
IL136635A0 (en) 2001-06-14
CN1288385A (zh) 2001-03-21
ZA99168B (en) 2000-07-11
KR20010024855A (ko) 2001-03-26
AU746284B2 (en) 2002-04-18
US6136833A (en) 2000-10-24

Similar Documents

Publication Publication Date Title
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
KR900007837A (ko) 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법
UY27320A1 (es) Nuevas composiciones farmacéuticas
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
BR0104228A (pt) Derivados do ácido de alquilamino úteis como agentes farmacêuticos, método para fabricação de um composto, composição farmacêutica, métodos para tratamentos diversos e uso de um composto na fabricação de um medicamento para tratamentos diversos
US4771073A (en) Rectally absorbable form of L-dopa
BR9913575A (pt) Composições compreendendo sais de amina simpatomimética inadequadas para uso ilegal
BR0014869A (pt) Composição e método para estabilização da mesma
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
BR0309439A (pt) Sais de tolterodina
KR970025615A (ko) 암 전이 억제제
RU2002103315A (ru) Офтальмическая композиция, содержащая кетотифен
US4873263A (en) Rectally absorbable form of L-dopa
BR9907166A (pt) Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
KR950031084A (ko) 국소용 진양(鎭洋) 조성물
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
KR880002518A (ko) 소염제 조성물
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
PT93991A (pt) Processo para a preparacao de solucoes estaveis de analogos de rebecamicina
KR880002507A (ko) 페닐퀴놀린 카복실산의 동결건조 약제 조성물
AR002981A1 (es) Un envase que aloja una composicion farmaceutica que comprende una solucion acuosa de clorhidrato de procaterol, y una composicion farmaceutica quecomprende una solucion acuosa de clorhidrato de procaterol
KR930023338A (ko) 데포우 제제
ES8205394A1 (es) Procedimiento para preparar esteres de l-arginina en solu- cion acuosa

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.